This Government Contract opportunity from Department Of Health And Human Services was posted on May 22, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
INTENT TO SOLE SOURCE gPROMS Lyophilization Modeling Toolbox (or equal)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The FDA's Center for Drug Evaluation and Research (CDER), specifically the Office of Pharmaceutical Quality Research, is seeking to acquire an advanced lyophilization process modeling and simulation platform to enhance the study of emerging pharmaceutical manufacturing technologies. The contract titled "INTENT TO SOLE SOURCE gPROMS Lyophilization Modeling Toolbox (or equal)" aims to secure this specialized software solution to support their research activities. This opportunity was posted on May 22, 2026, with responses due by June 2, 2026. The procurement will be managed by the FDA Office of Acquisitions and Grants Services, part of the Department of Health and Human Services, operating out of Rockville, Maryland, with the project performance based in Silver Spring, Maryland. This is a special notice without any set-aside restrictions, categorized under NAICS code 513210, which pertains to software publishers. The point of contact for this procurement is Terina Hicks, who can be reached via email. The platform sought is intended to provide the FDA with cutting-edge tools for process simulation and modeling, critical for advancing pharmaceutical manufacturing research and quality assessment.
General Info
Agency
NAICS
Place of Performance
Silver Spring, MD, 20993, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The FDA / Center for Drug Evaluation and Research (CDER) / Office of Pharmaceutical Quality Research (OPQR) requires to obtain an advanced lyophilization process modeling and simulation platform to study emerging pharmaceutical manufacturing technologies.
Please review the attached Intent to Sole Source FDA-75F40126Q00155 document for more information.
